Zonulin, regulation of tight junctions, and autoimmune diseases

Annals of the New York Academy of Sciences

Volumn 1258, Issue 1, 2012, Pages 25-33

  Fasano, Alessio ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Intestine; Tight junctions; Zonulin

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTIGEN; AT 1002; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GLIADIN; GLUTEN; LARAZOTIDE; PLACEBO; POLYCLONAL ANTIBODY; PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE ACTIVATED RECEPTOR 2; UNCLASSIFIED DRUG; ZONULIN;

ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTONOMIC NEUROPATHY; CELIAC DISEASE; CELL ULTRASTRUCTURE; CHRONIC KIDNEY DISEASE; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; GENOTYPE; GLUTEN FREE DIET; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE ABSORPTION; INTESTINE MOTILITY; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; MEMBRANE TRANSPORT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; TIGHT JUNCTION; TREATMENT OUTCOME; WESTERN BLOTTING;

EID: 84862983459     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06538.x     Document Type: Article

References (58)

1. Okada, H., C. Kuhn & H. Feillet 2010. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. Clin. Exp. Immunol. 2010: 1-9.
2. Progress in Autoimmune Diseases Research, Report to Congress, National Institutes of Health, The Autoimmune Diseases Coordinating Committee, March 2005.
3. National Institutes of Health Autoimmune Diseases research Plan 2002.
4. Tao, B., M. Pietropaolo, M. Atkinson, et al 2010. Estimating the cost of type 1 diabetes in the USA propensity score matching method. PLoS One 5: 1-11.
5. Arrieta, M.C., L. Bistritz & J.B. Meddings 2006. Alterations in intestinal permeability. Gut 55: 1512-1520.
6. Fasano, A. & T. Shea-Donohue 2005. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 416-422.
7. Wapenaar, M.C., A.J. Monsuur, A.A. van Bodegraven, et al 2008. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. Gut 57: 463-467.
8. Monsuur, A.J., P.I. de Bakker, B.Z. Alizadeh, et al 2005. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat. Genet. 37: 1341-1344.
9. Ménard, S., N. Cerf-Bensussan & M. Heyman 2010. Multiple facets of intestinal permeability and epithelial handling of dietary antigens. Mucosal. Immunol. 3: 247-259.
10. Chieppa, M., M. Rescigno, A.Y. Huang & R.N. Germain 2006. Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement. J. Exp. Med. 203: 2841-2852.
11. Mowat, A.M., O.R. Millington & F.G. Chirdo 2004. Anatomical and cellular basis of immunity and tolerance in the intestine. J. Pediatr. Gastroenterol. Nutr. 39: S723-S724.
12. Wang, W., S. Uzzau, S.E. Goldblum & A. Fasano 2000. Human zonulin, a potential modulator of intestinal tight junctions. J. Cell Sci. 113: 4435-4440.
13. Fasano, A., T. Not, W. Wang, et al 2000. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet 355: 1518-1519.
14. Fasano, A. 2000. Regulation of intercellular tight junctions by zonula occludens toxin and its eukaryotic analogue zonulin. Ann. N. Y. Acad. Sci. 915: 214-222.
15. Sapone, A., L. de Magistris, M. Pietzak, et al 2006. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 55: 1443-1449.
16. Watts, T., I. Berti, A. Sapone, et al 2005. Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc. Natl. Acad. Sci. USA 102: 2916-2921.
17. Paterson, B.M., K.M. Lammers, M.C. Arrieta, et al 2007. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment. Pharmacol. Ther. 26: 757-766.
18. Fasano, A. 2011. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol. Rev. 91: 151-175.
19. Tripathi, A., K.M. Lammers, S. Goldblum, et al 2009. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc. Natl. Acad. Sci. USA 106: 16799-16804.
20. Bjorkman, P.J., M.A. Saper, B. Samraoui, et al 1987. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329: 506-512.
21. Asleh, R., S. Marsh, M. Shilkrut, et al 2003. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ. Res. 92: 1193-1200.
22. Wicher, K.B. & E. Fries 2004. Prohaptoglobin is proteolytically cleaved in the endoplasmic reticulum by the complement C1r-like protein. Proc. Natl. Acad. Sci. USA 101: 14390-14395.
23. Drago, S., A.R. El, P.M. Di, et al 2006. Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand. J. Gastroenterol. 41: 408-419.
24. Hollande, F., E.M. Blanc, J.P. Bali, et al 2001. HGF regulates tight junctions in new nontumorigenic gastric epithelial cell line. Am. J. Physiol. Gastrointest. Liver Physiol. 280: G910-G921.
25. Jin, M., E. Barron, S. He, et al 2002. Regulation of RPE intercellular junction integrity and function by hepatocyte growth factor. Invest. Ophthalmol. Vis. Sci. 43: 2782-2790.
26. van der Merwe, J.Q., M.D. Hollenberg & W.K. MacNaughton 2008. EGF receptor transactivation and MAP kinase mediate proteinase-activated receptor-2-induced chloride secretion in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G441-G451.
27. Goldblum, S.E., U. Rai, A. Tripathi, et al 2011. The active Zot domain (aa 288-293) increases ZO-1 and myosin 1C serine/threonine phosphorylation, alters interaction between ZO-1 and its binding partners, and induces tight junction disassembly through proteinase activated receptor 2 activation. FASEB J. 25: 144-158.
28. El Asmar, R., P. Panigrahi, P. Bamford, et al 2002. Host-dependent activation of the Zonulin system is involved in the impairment of the gut barrier function following bacterial colonization. Gastroenterology 123: 1607-1615.
29. Clemente, M.G., S. De Virgiliis, J.S. Kang, et al 2003. Early effects of gliadin on enterocyte intracellular signaling involved in intestinal barrier function. Gut 52: 218-223.
30. Lammers, K.M., R. Lu, J. Brownley, et al 2008. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology 135: 194-204.
31. Branski, D., A. Fasano & R. Troncone 2006. Latest developments in the pathogenesis and treatment of celiac disease. J. Pediatr. 149: 295-300
32. Plenge, R.M. 2010. Unlocking the pathogenesis of celiac disease. Nat. Genet. 42: 281-282.
33. Madara, J.L. & J.S. Trier 1980. Structural abnormalities of jejunal epithelial cell membranes in celiac sprue. Lab. Inves. 43: 254-261.
34. Wolters, V.M., B.Z. Alizadeh, M.E. Weijerman, et al 2010. Intestinal barrier gene variants may not explain the increased levels of antigliadin antibodies, suggesting other mechanisms than altered permeability. Hum. Immunol. 71: 392-396.
35. Szakál, D.N., H. Gyorffy, A. Arató, et al 2010. Mucosal expression of claudins 2, 3 and 4 in proximal and distal part of duodenum in children with coeliac disease. Virchows Arch. 456: 245-250.
36. Schumann, M., D. Günzel, N. Buergel, et al 2012. Cell polarity-determining proteins Par-3 and PP-1 are involved in epithelial tight junction defects in coeliac disease. Gut 61: 220-228.
37. Arentz-Hansen, H., S. McAdam, O. Molberg, et al 2003. Celiac lesion T cells recognized epitopes that cluster in regions of gliadin rich in proline residues. Gastroenterology 123:803-809.
38. Nikulina, M. et al 2004. Wheat gluten causes dendritic cell maturation and chemokine secretion. J. Immunol. 173: 1925-1933.
39. Fasano, A. 2001. Pathological and therapeutical implications of macromolecule passage through the tight junction. In Tight Junctions. 697-722. CRC Press, Inc., Boca Raton, FL
40. Fasano, A. 2008. Physiological, pathological, and therapeutic implications of zonulin-mediated intestinal barrier modulation: living life on the edge of the wall. Am. J. Pathol. 173: 1243-1252.
41. Brorsson, C., N. Tue Hansen, R. Bergholdt, et al 2010. The type 1 diabetes-HLA susceptibility interactome-identification of HLA genotype-specific disease genes for type 1 diabetes. PLoS One. 5: e9576.
42. Feldman, M. & L.R. Schiller 1983. Disorders of gastrointestinal motility associated with diabetes mellitus. Ann. Intern. Med. 98: 378-384.
43. De Magistris, L., M. Secondulfo, D. Iafusco, et al 1996. Altered mannitol absorption in diabetic children. Ital. J. Gastroenterol. 28: 367.
44. Mooradian, A.D., J.E. Morley, A.S. Levine, et al 1996. Abnormal intestinal permeability to sugars in diabetes mellitus. Diabetologia 29: 221-224.
45. Meddings, J.B., J. Jarand, S.J. Urbanski, et al 1999. Increased gastrointestinal permeability is an early lesion in the spontaneously diabetic BB rat. Am. J. Physiol. 276: G951-G957.
46. Funda, D.P. & A. Kaas, H. Tlaskalová-Hogenová & K. Buschard 2008. Gluten-free but also gluten-enriched (gluten+) diet prevent diabetes in NOD mice; the gluten enigma in type 1 diabetes. Diabetes Metab. Res. Rev. 24: 59-63.
47. Visser, J.T., K. Lammers, A. Hoogendijk, et al 2010. Restoration of impaired intestinal barrier function by the hydrolysed casein diet contributes to the prevention of type 1 diabetes in the diabetes-prone BioBreeding rat. Diabetologia. 53: 2621-2628.
48. Simpson, M., M. Mojibian, K. Barriga, et al 2009. An exploration of Glo-3A antibody levels in children at increased risk for type 1 diabetes mellitus. Pediatr. Diabetes 10: 563-572.
49. Melamed-Frank, M., O. Lache, B.I. Enav, et al 2001. Structure-function analysis of the antioxidant properties of haptoglobin. Blood 98: 3693-3698.
50. Blum, S., U. Milman, C. Shapira & A.P. Levy 2008. Pharmacogenomic application of the haptoglobin genotype in the prevention of diabetic cardiovascular disease. Pharmacogenomics 9: 989-991.
51. Papp, M., I. Foldi, E. Nemes, et al 2008. Haptoglobin polymorphism: a novel genetic risk factor for celiac disease development and its clinical manifestations. Clin. Chem. 54: 697-704.
52. Napolioni, V., P. Giannì, F.M. Carpi, et al 2011. Haptoglobin (HP) polymorphisms and human longevity: a cross-sectional association study in a Central Italy population. Clin. Chim. Acta. 412: 574-577.
53. Márquez, L. et al 2012. Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis. Gut 61: 528-534.
54. Wan, C. et al 2007. Abnormal changes of plasma acute phase proteins in schizophrenia and the relation between schizophrenia and haptoglobin (Hp) gene. Amino. Acids 32: 101-108.
55. Chen, Y. C. et al 2011. Haptoglobin polymorphism as a risk factor for chronic kidney disease: a case-control study. Am. J. Nephrol. 33: 510-514.
56. Fasano, A. 2009. Surprises from celiac disease. Sci. Am. 301: 54-61.
57. Paterson, B.M., K.M. Lammers, M.C. Arrieta, et al 2007. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in celiac disease subjects: a proof of concept study. Aliment. Pharmacol. Ther. 26: 757-766.
58. Kelly, C.P., P.H. Green, J.A. Murray, et al 2009. Safety, tolerability and effects on intestinal permeability of larazotide acetate in celiac disease: results of a phase IIB 6-week gluten-challenge clinical trial. Gastro. 136, 5: A-474.